Evidence map›Paper›PMID 37894510›Full record

ArticleMolecules (Basel, Switzerland)2023

Exploring the HIV-1 Rev Recognition Element (RRE)-Rev Inhibitory Capacity and Antiretroviral Action of Benfluron Analogs.

Sergi Chumillas, Saurabh Loharch, Manuela Beltrán, Mateusz P Szewczyk, Silvia Bernal, Maria C Puertas, Javier Martinez-Picado, José Alcamí, Luis M Bedoya, Vicente Marchán and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Sergi ChumillasDepartament de Química Inorgànica i Orgànica, Secció de Química Orgànica, IBUB, Universitat de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0002-0173-6031
Saurabh LoharchCentro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain.ORCID 0000-0002-5496-8784
Manuela BeltránInstituto de Salud Carlos III, 28220 Majadahonda, Spain.ORCID 0000-0001-6185-2280
Mateusz P SzewczykCentro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain.ORCID 0000-0001-9533-5687
Silvia BernalIrsiCaixa AIDS Research Institute, 08916 Badalona, Spain.ORCID 0000-0003-4991-0008
Maria C PuertasCIBERINFEC, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Javier Martinez-PicadoCIBERINFEC, Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-4916-2129
José AlcamíInstituto de Salud Carlos III, 28220 Majadahonda, Spain.ORCID 0000-0003-0023-7377
Luis M BedoyaInstituto de Salud Carlos III, 28220 Majadahonda, Spain.ORCID 0000-0001-6249-6847
Vicente MarchánDepartament de Química Inorgànica i Orgànica, Secció de Química Orgànica, IBUB, Universitat de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0002-1905-2156
José GallegoCentro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain.ORCID 0000-0002-0627-6927
Instituto de Salud Carlos III · ESValencia Catholic University Saint Vincent Martyr · ESUniversitat de Barcelona · ESUniversitat de Vic - Universitat Central de Catalunya · ESUniversidad Complutense de Madrid · ES

Funding

Generalitat Valenciana PROMETEO 2021/036
6 · The paper itself

Abstract

Human immunodeficiency virus-type 1 (HIV-1) remains one of the leading contributors to the global burden of disease, and novel antiretroviral agents with alternative mechanisms are needed to cure this infection. Here, we describe an exploratory attempt to optimize the antiretroviral properties of benfluron, a cytostatic agent previously reported to exhibit strong anti-HIV activity likely based on inhibitory actions on virus transcription and Rev-mediated viral RNA export. After obtaining six analogs designed to modify the benzo[c]fluorenone system of the parent molecule, we examined their antiretroviral and toxicity properties together with their capacity to recognize the Rev Recognition Element (RRE) of the virus RNA and inhibit the RRE-Rev interaction. The results indicated that both the benzo[c] and cyclopentanone components of benfluron are required for strong RRE-Rev target engagement and antiretroviral activity and revealed the relative impact of these moieties on RRE affinity, RRE-Rev inhibition, antiviral action and cellular toxicity. These data provide insights into the biological properties of the benzo[c]fluorenone scaffold and contribute to facilitating the design of new anti-HIV agents based on the inhibition of Rev function.

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsFluorenesHumansNucleic Acid Conformationrev Gene Products, Human Immunodeficiency VirusRNA, ViralAnti-HIV AgentsFluorenesrev Gene Products, Human Immunodeficiency VirusRNA, ViralVUFB 13468antiviral drug discoverybenfluronbenzo[c]fluorenonehuman immunodeficiency virus type 1RevRNA

Identifiers

PMID37894510
PMCPMC10609163
OpenAlexW4387530222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.